LitAlert ~~ GeneLit.com

    • Olaparib in gBRCA+ Breast Cancer; 'Clearly Practice Changing'.
    • Worcester S.
    • Medscape Oncology. 2022 Mar 18.
    • Influence of cellular models and individual factor in the biological response to chest CT scan exams.
    • Devic C, Bodgi L, Sonzogni L, Pilleul F, Ribot H, Charry C, Le Moigne F, Paul D, Carbillet F, Munier M, Foray N.
    • Eur Radiol Exp. 2022 Mar 17;6(1):14. doi: 10.1186/s41747-022-00266-0.
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC., Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; On behalf of theCHARM Study.
    • Genet Med. 2022 Mar 16. doi: 10.1016/j.gim.2022.02.006. Epub ahead of print.
    • A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family.
    • Hu PZ, Chen XY, Xiong W, Yang ZJ, Li XR, Deng WZ, Gong LN, Deng H, Yuan LM.
    • Curr Med Sci. 2022 Mar 15. doi: 10.1007/s11596-022-2527-2. Epub ahead of print.
    • Case report
    • BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.
    • Bradbury M, Borràs E, Castellví J, Méndez O, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Sabidó E, Santamaria A.
    • Sci Rep. 2022 Mar 15;12(1):4445. doi: 10.1038/s41598-022-08461-0.
    • The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population.
    • Luo Y, Wu H, Huang Q, Rao H, Yu Z, Zhong Z.
    • Int J Gen Med. 2022 Mar 10;15:2773-2786. doi: 10.2147/IJGM.S355755.
    • Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum.
    • Musaddaq B, Brown A, Dluzewski S, Marafioti T, Malhotra A.
    • BJR Case Rep. 2022 Mar 9;7(6):20210063. doi: 10.1259/bjrcr.20210063.
    • BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies.
    • Fu X, Tan W, Song Q, Pei H, Li J.
    • Front Cell Dev Biol. 2022 Mar 1;10:813457. doi: 10.3389/fcell.2022.813457.
    • [A Case of Breast Cancer during Pregnancy Treated with Neoadjuvant Chemotherapy during Pregnancy].
    • Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, Noda H, Taguchi K, Nishiyama K, Murakami A, Yamashita M, Kamei Y, Takada Y.
    • Gan To Kagaku Ryoho. 2022 Mar;49(3):289-292. Japanese.
    • Case report. [Article in Japanese]
    • Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.
    • Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, Zhu J, Gadi VK, Ronen R, Stilwell J, Kaldjian E, Dutkowski J, Benz SC, Rabizadeh S, Soon-Shiong P, Blau CA.
    • JCO Precis Oncol. 2022 Mar;6:e2100280. doi: 10.1200/PO.21.00280.
    • PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    • Miller RE, El-Shakankery KH, Lee JY.
    • J Gynecol Oncol. 2022 Mar;33:e44. doi: 10.3802/jgo.2022.33.e44.
    • Identification of the c.829_832delAATA Deletion Variants in the BRCA1 Gene Associated with Hereditary Breast/Ovarian Cancer - Case Report.
    • Ostrowska M, Olszewska-Bozek K, Podlodowska J, Sierocinska-Sawa J, Wojcierowski J.
    • J Genomics. 2022 Feb 14;10:33-38. doi: 10.7150/jgen.68220.